Artwork

Inhoud geleverd door VJHemOnc. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door VJHemOnc of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Player FM - Podcast-app
Ga offline met de app Player FM !

The MPN Sessions: highlights from EHA and ASCO 2021

29:17
 
Delen
 

Manage episode 297617692 series 2838329
Inhoud geleverd door VJHemOnc. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door VJHemOnc of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

Over the past decade there has been a vast increase in the number of clinical trials taking place in the field of myeloproliferative neoplasms (MPNs), with many trials investigating the potential benefits of novel JAK inhibitors both as monotherapy and in combination with other drugs, such as Bcl-2, Bcl-xL or BET inhibitors. More recently, next-generation sequencing has led to the identification of further mutations associated with MPNs, which may provide alternative therapeutic targets. In particular, the telomerase inhibitor imetelstat and the MDM2 inhibitor KRT-232, have demonstrated potential benefits for patients with myelofibrosis, whilst the tyrosine kinase inhibitor avapritinib recently received FDA approval for the treatment of advanced systemic mastocytosis.

In this roundtable discussion, leading MPN experts Ruben Mesa, MD, from the UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, and Naveen Pemmaraju, MD, of The University of Texas MD Anderson Cancer Center, review the top highlights from the 2021 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) meetings, including data on novel JAK inhibitors and combination regimens, therapies for rarer MPNs and updates from ongoing Phase III trials of key treatments.

  continue reading

200 afleveringen

Artwork
iconDelen
 
Manage episode 297617692 series 2838329
Inhoud geleverd door VJHemOnc. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door VJHemOnc of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

Over the past decade there has been a vast increase in the number of clinical trials taking place in the field of myeloproliferative neoplasms (MPNs), with many trials investigating the potential benefits of novel JAK inhibitors both as monotherapy and in combination with other drugs, such as Bcl-2, Bcl-xL or BET inhibitors. More recently, next-generation sequencing has led to the identification of further mutations associated with MPNs, which may provide alternative therapeutic targets. In particular, the telomerase inhibitor imetelstat and the MDM2 inhibitor KRT-232, have demonstrated potential benefits for patients with myelofibrosis, whilst the tyrosine kinase inhibitor avapritinib recently received FDA approval for the treatment of advanced systemic mastocytosis.

In this roundtable discussion, leading MPN experts Ruben Mesa, MD, from the UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, and Naveen Pemmaraju, MD, of The University of Texas MD Anderson Cancer Center, review the top highlights from the 2021 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) meetings, including data on novel JAK inhibitors and combination regimens, therapies for rarer MPNs and updates from ongoing Phase III trials of key treatments.

  continue reading

200 afleveringen

Alle afleveringen

×
 
Loading …

Welkom op Player FM!

Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.

 

Korte handleiding